COSMOS Pharmaceutical Cor... (CSMYF)
COSMOS Pharmaceutical Statistics
Share Statistics
COSMOS Pharmaceutical has 79.26M shares outstanding. The number of shares has increased by 100% in one year.
| Shares Outstanding | 79.26M |
| Shares Change (YoY) | 100% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 37.28M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 25.05 and the forward PE ratio is null. COSMOS Pharmaceutical's PEG ratio is -0.51.
| PE Ratio | 25.05 |
| Forward PE | n/a |
| PS Ratio | 0.63 |
| Forward PS | n/a |
| PB Ratio | 2.65 |
| P/FCF Ratio | -964.56 |
| PEG Ratio | -0.51 |
Enterprise Valuation
COSMOS Pharmaceutical has an Enterprise Value (EV) of 594.25B.
| EV / Sales | 0.62 |
| EV / EBITDA | 11.06 |
| EV / EBIT | 10.77 |
| EV / FCF | -935.83 |
Financial Position
The company has a current ratio of 0.72, with a Debt / Equity ratio of 0.15.
| Current Ratio | 0.72 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.63 |
| Debt / FCF | -53.64 |
| Interest Coverage | 318.19 |
Financial Efficiency
Return on Equity is 10.57% and Return on Invested Capital is 8.47%.
| Return on Equity | 10.57% |
| Return on Assets | 5.13% |
| Return on Invested Capital | 8.47% |
| Revenue Per Employee | $175.07M |
| Profits Per Employee | $4.44M |
| Employee Count | 5,512 |
| Asset Turnover | 2.02 |
| Inventory Turnover | 9.01 |
Taxes
| Income Tax | 9.27B |
| Effective Tax Rate | 27.48% |
Stock Price Statistics
The stock price has increased by -6.31% in the last 52 weeks. The beta is 0.28, so COSMOS Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.28 |
| 52-Week Price Change | -6.31% |
| 50-Day Moving Average | 46.06 |
| 200-Day Moving Average | 43.1 |
| Relative Strength Index (RSI) | 34.05 |
| Average Volume (20 Days) | 13 |
Income Statement
In the last 12 months, COSMOS Pharmaceutical had revenue of 964.99B and earned 24.45B in profits. Earnings per share was 308.61.
| Revenue | 964.99B |
| Gross Profit | 188.31B |
| Operating Income | 31.5B |
| Net Income | 24.45B |
| EBITDA | 53.74B |
| EBIT | 33.82B |
| Earnings Per Share (EPS) | 308.61 |
Balance Sheet
The company has 52.3B in cash and 34.06B in debt, giving a net cash position of 18.24B.
| Cash & Cash Equivalents | 52.3B |
| Total Debt | 34.06B |
| Net Cash | 18.24B |
| Retained Earnings | 222.28B |
| Total Assets | 476.55B |
| Working Capital | -58.9B |
Cash Flow
In the last 12 months, operating cash flow was 55.17B and capital expenditures -55.81B, giving a free cash flow of -635M.
| Operating Cash Flow | 55.17B |
| Capital Expenditures | -55.81B |
| Free Cash Flow | -635M |
| FCF Per Share | -8.01 |
Margins
Gross margin is 19.51%, with operating and profit margins of 3.26% and 2.53%.
| Gross Margin | 19.51% |
| Operating Margin | 3.26% |
| Pretax Margin | 3.49% |
| Profit Margin | 2.53% |
| EBITDA Margin | 5.57% |
| EBIT Margin | 3.26% |
| FCF Margin | -0.07% |
Dividends & Yields
CSMYF pays an annual dividend of $0.41, which amounts to a dividend yield of 1.04%.
| Dividend Per Share | $0.41 |
| Dividend Yield | 1.04% |
| Dividend Growth (YoY) | -7.19% |
| Payout Ratio | 17.51% |
| Earnings Yield | 3.99% |
| FCF Yield | -0.1% |
Analyst Forecast
Currently there are no analyst rating for CSMYF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 23, 2024. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 23, 2024 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 2.75 |
| Piotroski F-Score | 5 |